Acadian Asset Management
IOBT

Acadian Asset Management’s IO Biotech IOBT Stock Holding History

Acadian Asset Management’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-23,366
Closed -$32K – 1910
2025
Q2 		$32K Sell
23,366
-7,492
-24% -$8.58K ﹤0.01% 1535
2025
Q1 		$33K Sell
30,858
-29,792
-49% -$28.1K ﹤0.01% 1484
2024
Q4 		$54K Hold
60,650
– – ﹤0.01% 1443
2024
Q3 		$63K Buy
+60,650
New +$76.4K ﹤0.01% 1740

Other funds holding IOBT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Acadian Asset Management's IOBT Position: Q3 2025 in Review

Acadian Asset Management sold out of IO Biotech (IOBT) in Q3 2025, closing a stake of 23,366 shares — an estimated $32K sold.

Acadian Asset Management first reported a position in IOBT in Q3 2024 and held it in 4 quarters. The position peaked at $63K in Q3 2024. 21 funds tracked by Wall St. Rank hold IOBT as of Q3 2025.

  • Acadian Asset Management reported no remaining IO Biotech position as of Q3 2025 after selling out during the quarter.
  • Acadian Asset Management sold 23,366 IO Biotech shares in Q3 2025, an estimated $32K.
  • Acadian Asset Management first reported a position in IO Biotech in Q3 2024 and held it in 4 quarters.
  • Acadian Asset Management's IO Biotech position peaked at $63K in Q3 2024.
  • 21 funds tracked by Wall St. Rank held IO Biotech as of Q3 2025.

Based on Acadian Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.